Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amarin Corp ADR (NQ: AMRN )

0.8807 -0.0393 (-4.27%)
Streaming Delayed Price Updated: 3:27 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amarin Corp ADR

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023
From Amarin Corporation plc
Via GlobeNewswire
Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP
From Amarin Corporation plc
Via GlobeNewswire
Amarin To Rally 138%? Here Are 10 Other Analyst Forecasts For Friday
Via Benzinga
Amarin to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Amarin Corporation plc
Via GlobeNewswire
Why Amarin Stock Was a Winner Today
The product most readily identified with the company will soon hit pharmacy shelves in Australia. 
Via The Motley Fool
Amarin (AMRN) Q3 2022 Earnings Call Transcript
AMRN earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Amarin Corp: Q3 Earnings Insights
Amarin Corp (NASDAQ:AMRN) reported its Q3 earnings results on Thursday, October 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
Via Benzinga
Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland
From Amarin Corporation plc
Via GlobeNewswire
Amarin Touts Positive Data For Its Heart Disease Drug In Current/Former Smokers
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
Via Benzinga
Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Present at Jefferies London Healthcare Conference
From Amarin Corporation plc
Via GlobeNewswire
Amarin Highlights Key Data Presented at American Heart Association 2022 Scientific Sessions for VASCEPA®/VAZKEPA (icosapent ethyl) and Patient Care
From Amarin Corporation plc
Via GlobeNewswire
Amarin Corp Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q3, Amarin Corp's (NASDAQ:AMRN) reported sales totaled $89.88 million. Despite a 92.65% increase in earnings, the company posted a loss of $5.14 million. 
Via Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870. 
Via Benzinga
Earnings Preview For Amarin Corp
Amarin Corp (NASDAQ:AMRN) is set to give its latest quarterly earnings report on Thursday, 2022-10-27. Here's what investors need to know before the announcement. Analysts estimate that Amarin Corp... 
Via Benzinga
Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022
From Amarin Corporation plc
Via GlobeNewswire
Amarin Board of Directors Issues Statement in Response to Sarissa
From Amarin Corporation plc
Via GlobeNewswire
Sarissa Capital Has Commenced the Process to Call a Special Meeting of Amarin Shareholders to Remove and Replace Certain Board Members
From Sarissa Capital Management LP
Via Business Wire
3 Biotech Stocks Gaining Momentum
The headlines have been particularly good for a trio of small cap biotechs and it appears the momentum may have staying power. 
Via MarketBeat
MarketBeat: Week in Review 8/22 - 8/26
The markets are selling on news that interest rate hikes will continue past September. But here are some of the other stories for investors to follow this week 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Amarin's New Vascepa Data Shows Significant Reduction In Heart Attack Subtypes
New data shows that Amarin Corporation plc's (NASDAQ: AMRN) Vascepa/Vazkepa (icosapent ethyl) significantly reduced ST-segment and non-ST elevation myocardial infarction (NSTEMI) and other MI subtypes... 
Via Benzinga
7 F-Rated Growth Stocks to Sell Before Q4
Challenging market conditions make these growth stocks to sell a detriment to your portfolio if you don't dump them before Q4. 
Via InvestorPlace
Are Ocugen or Amarin Good Penny Stocks to Buy?
This article discusses the current state of Ocugen and Amarin, two penny stocks that highlight the risk and (potential) reward of penny stock investing. 
Via MarketBeat
Why Amazon Shares Traded Lower; Here Are 74 Biggest Movers From Yesterday
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 72.8% to close at $2.16 on Monday as the stock continued to see momentum despite the company last week announcing it is not aware of... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.